Cargando…
A RESPONSE TO “THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER”
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391022/ https://www.ncbi.nlm.nih.gov/pubmed/33251994 http://dx.doi.org/10.18553/jmcp.2020.26.12.1616 |
| _version_ | 1785082607115960320 |
|---|---|
| author | Ogale, Sarika Zerbini, Clarissa Emy Higuchi Antoniou, Miranta Freund, Romain |
| author_facet | Ogale, Sarika Zerbini, Clarissa Emy Higuchi Antoniou, Miranta Freund, Romain |
| author_sort | Ogale, Sarika |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10391022 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Academy of Managed Care Pharmacy |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103910222023-08-02 A RESPONSE TO “THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER” Ogale, Sarika Zerbini, Clarissa Emy Higuchi Antoniou, Miranta Freund, Romain J Manag Care Spec Pharm Letters Academy of Managed Care Pharmacy 2020-12 /pmc/articles/PMC10391022/ /pubmed/33251994 http://dx.doi.org/10.18553/jmcp.2020.26.12.1616 Text en Copyright © 2020, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
| spellingShingle | Letters Ogale, Sarika Zerbini, Clarissa Emy Higuchi Antoniou, Miranta Freund, Romain A RESPONSE TO “THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER” |
| title | A RESPONSE TO “THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER” |
| title_full | A RESPONSE TO “THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER” |
| title_fullStr | A RESPONSE TO “THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER” |
| title_full_unstemmed | A RESPONSE TO “THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER” |
| title_short | A RESPONSE TO “THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER” |
| title_sort | response to “the potential long-term comparative effectiveness of larotrectinib and entrectinib for second-line treatment of trk fusion-positive metastatic lung cancer” |
| topic | Letters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391022/ https://www.ncbi.nlm.nih.gov/pubmed/33251994 http://dx.doi.org/10.18553/jmcp.2020.26.12.1616 |
| work_keys_str_mv | AT ogalesarika aresponsetothepotentiallongtermcomparativeeffectivenessoflarotrectinibandentrectinibforsecondlinetreatmentoftrkfusionpositivemetastaticlungcancer AT zerbiniclarissaemyhiguchi aresponsetothepotentiallongtermcomparativeeffectivenessoflarotrectinibandentrectinibforsecondlinetreatmentoftrkfusionpositivemetastaticlungcancer AT antonioumiranta aresponsetothepotentiallongtermcomparativeeffectivenessoflarotrectinibandentrectinibforsecondlinetreatmentoftrkfusionpositivemetastaticlungcancer AT freundromain aresponsetothepotentiallongtermcomparativeeffectivenessoflarotrectinibandentrectinibforsecondlinetreatmentoftrkfusionpositivemetastaticlungcancer AT ogalesarika responsetothepotentiallongtermcomparativeeffectivenessoflarotrectinibandentrectinibforsecondlinetreatmentoftrkfusionpositivemetastaticlungcancer AT zerbiniclarissaemyhiguchi responsetothepotentiallongtermcomparativeeffectivenessoflarotrectinibandentrectinibforsecondlinetreatmentoftrkfusionpositivemetastaticlungcancer AT antonioumiranta responsetothepotentiallongtermcomparativeeffectivenessoflarotrectinibandentrectinibforsecondlinetreatmentoftrkfusionpositivemetastaticlungcancer AT freundromain responsetothepotentiallongtermcomparativeeffectivenessoflarotrectinibandentrectinibforsecondlinetreatmentoftrkfusionpositivemetastaticlungcancer |